Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of October 2025, with a specific report date of October 2, 2025. Haleon Plc is a global leader in consumer health, operating across six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory disclosure regarding corporate governance and does not contain financial performance data.
Material Changes
The primary material change disclosed is a corporate governance update. Tracy Clarke, a Non-Executive Director of Haleon, has been appointed to the Board of Inchcape plc (LSE: INCH) as a Non-Executive Director, effective December 31, 2025. This appointment is made in accordance with paragraph 6.4.9R(2) of the UK Listing Rules.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on market conditions, or specific risk factors. The document serves solely as a Director Declaration regarding the external board appointment of Tracy Clarke.
Key Facts for Investor Verification
- Tracy Clarke will join the board of Inchcape plc on December 31, 2025.
- This filing is a compliance report under UK Listing Rules and does not include financial results.
- Haleon continues to operate its six core consumer health categories with its established brand portfolio.